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Identity 
Other names: FLJ21080, KMT3E, MGC104324, 
ZMYND1, ZNFN3A1, bA74P14.1 
HGNC (Hugo): SMYD3 
Location: 1q44 
Local order: The human SMYD3 gene maps on 1q44 
between the LOC100132379 and the KIF26B loci. 
DNA/RNA 
 
Genomic organization of SMYD3. The SMYD3 gene is 
comprised of 12 exons and encodes for two alternatively 
transcript variants that use different first exon and promoter. 
Description 
The SMYD3 gene is comprised of 12 exons, spanning 
757.8 kb on chromosome 1q44. Two transcript variants 
were encoded using different first exon and promoter.  
A variable number of tandem repeats (VNTR) 
polymorphism in E2F-1-binding element in the 
promoter region of SMYD3 transcript variant 1 has  
been shown to be significantly associated with an 
increased risk of colorectal cancer, hepatocellular 
carcinoma and breast cancer in Japanese population 
(Tsuge et al., 2005). It is also shown that this VNTR 
polymorphism might be a susceptibility factor for 
human esophageal squamous cell carcinoma in relation 
to tobacco smoking (Wang H et al., 2008). However, it 
seemed that this polymorphism was not associated with 
the cancer risk in all the races in the world (Frank et al., 
2006; Wang et al., 2007).  
A copy-number variation (CNV) on chromosome 1 was 
observed to be proximal to SMYD3 that displayed high 
expression in the lymphoblastoid cell lines, and this 
CNV was significantly associated with 1-beta-D-
arabinofuranosylcytosine cytotoxicity (Kalari et al., 
2010). 
Transcription 
The SMYD3 gene mainly has two transcript variants of 
1641 and 1469 bp, each comprising 12 exons. They 
differ for the alternative usage of the different first 
exon and promoter. The variant 2 is shorter at the N-
terminus, compared to the variant 1. Besides, there was 
a report showed that another SMYD3 transcript variant, 
termed SMYD3-NY, was detected in adult human testis 
and spermatozoa using the methods of hybridization 
with a human cDNA microarray (Zhou et al., 2005). 
However, SMYD3-NY has not been further confirmed 
with experimental evidence yet. 
Pseudogene 
Not yet described. 
 
 
Protein domains of SMYD3. SMYD3 has two isoforms. The isoform 2 (369 amino acids) just lacks 59 amino acid at the N-terminus of 
the isoform 1 (428 amino acids). 
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Protein 
Description 
The 1641 bp transcript variant 1 encodes a 428 amino 
acids protein containing a zf-MYND domain (49-87) 
and a SET domain (148-239), the transcript variant 2 
uses a downstream translational start codon and 
encodes a 369 amino acids protein which is 100% 
identical with the 60-428 region of the isoform 1. 
It has been shown that human cancer cells also express 
a cleaved form of SMYD3 lacking the 34 amino acids 
in the N-terminal region of the full-length SMYD3 
isoform 1. It seems that the N-terminal region of 
SMYD3 isoform 1 plays an important role for the 
regulation of its methyltransferase activity, and the 
cleavage of 34 amino acids in the N-terminal region or 
interaction with heat shock protein 90 alpha 
(HSP90alpha) may enhance the histone 
methyltransferase (HMTase) activity compared to the 
full-length protein (Silva et al., 2008). 
Expression 
SMYD3 is frequently up-regulated in colorectal 
carcinoma, hepatocellular carcinoma and breast cancer 
(Hamamoto et al., 2004; Hamamoto et al., 2006). miR-
124 can down-regulate SMYD3 through binding to 3' 
UTR of SMYD3 protein (Furuta et al., 2010). 
Localisation 
The SMYD3 protein is located mainly in the cytoplasm 
when the cells are arrested at G0/G1, but accumulated 
in the nuclei at S phase and G2/M (Hamamoto et al., 
2004). 
Function 
SMYD3 is a SET-domain-containing lysine histone 
methyltransferase which has been regarded as an 
important factor in carcinogenesis. Formed a complex 
with RNA polymerase II through an interaction with 
the RNA helicase HELZ, SMYD3 specifically 
methylates histone H3 at lysine 4 and activates the 
transcription of a set of downstream genes (including of 
Nkx2.8, hTERT, WNT10B, VEGFR1, c-Met, etc) 
containing a "5' - CCCTCC - 3'" or "5' - GGAGGG - 
3'" sequence in the promoter region, and these activities 
require protein cofactors HSP90alpha (Hamamoto et 
al., 2004; Liu et al., 2007; Hamamoto et al., 2006; 
Kunizaki et al., 2007; Zou et al., 2009). Enhanced 
expression of SMYD3 is essential for the growth of 
many cancer cells (such as colorectal carcinoma, 
hepatocellular carcinoma, breast cancer, etc), and it 
also could stimulate cell adhesion and migration, 
whereas suppression of SMYD3 by RNAi or other 
reagents induces apoptosis and inhibits cell 
proliferation and migration (Hamamoto et al., 2004; 
Hamamoto et al., 2006; Luo et al., 2007; Wang SZ et 
al., 2008; Zou et al., 2009; Chen et al., 2007; Luoet al., 
2010). 
SMYD3 may be an important coactivator of estrogen 
receptor (ER) in the estrogen signal pathway. It can
directly interact with the ligand binding domain of ER, 
in turn augments ER target gene expression via histone 
H3-K4 methylation (Kim et al., 2009). Besides, it has 
been shown that SMYD3 could interact with Jab1 in 
yeast cells and in vitro, and might be required for Jab1-
mediated enhancement of hemotopoietic progenitors 
cells (Mori et al., 2008). 
Homology 
SMYD3 displays structural homologies with other 
members of the SMYD histone methyltransferase 
family, such as the SMYD1 (30% identity, 50% 
similarity), SMYD2 (32% identity, 52% similarity), 
SMYD4 and SMYD5. 
Mutations 
Note 
Not yet described. A VNTR polymorphism in the 5' 
flanking region of SMYD3 has been reported as we 




SMYD3 expression is markedly elevated in colorectal 
cancers, and this upregulation enhances the growth f 
tumor cells (Hamamoto et al., 2004). 
Hepatocellular carcinoma 
Note 
SMYD3 was found to be overexpressed in human 
hepatocarcinoma cells, and silencing of SMYD3 by 
RNAi could inhibit cell proliferation and migration 
(Hamamoto et al., 2004; Zou et al., 2009; Chen et al., 
2007). miR-124, usually be epigenetically silenced in 
hepatocarcinoma cells, could downregulate SMYD3 
expression and inhibit cell growth (Furuta et al., 2010). 
Hepatitis B virus X protein could upregulate SMYD3 
expression in HepG2 hepatocellular carcinoma cell 
lines, and this effect might promote the progress of 
hepatoma (Yang et al., 2009). 
Breast cancer 
Note 
SMYD3 overexpression was observed in the great 
majority of breast cancer tissues, and suppression of 
SMYD3 by RNAi or other reagents could inhibit cell 
proliferation and migration (Hamamoto et al., 2006; 
Luo et al., 2010). Furthermore, SMYD3 was identified 
as a new coactivator for ER and was required in 
estrogen signal pathway (Kim et al., 2009). 
Cervical carcinoma 
Note 
Suppression of SMYD3 by RNAi could reduce cell 
proliferation, colony formation and migration/invasion 
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activity, and induces apoptosis in Hela cervical 
carcinoma cells (Wang SZ et al., 2008). 
Multiple myeloma 
Note 
Triptolide, an antitumor Chinese herb extracted 
ingredient, could decrease the expression of SMYD3 
and inhibit the proliferation of multiple myeloma cell 
line U266 in a time- and dose-dependent manner (Zhao 
et al., 2010). 
Esophageal squamous cell carcinoma 
Note 
A VNTR polymorphism in E2F-1-binding element in 
the promoter region of SMYD3 transcript variant 1 was 
observed to be a susceptibility factor for human 
esophageal squamous cell carcinoma in relation to 
tobacco smoking (Wang H et al., 2008). 
Breakpoints 
Note 
A breakpoint on 1q44 is located in the SMYD3 gene 
(Aktas et al., 2010). 
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